/* */ PELVIPHARM - Preclinical outsourcing CRO in sexual dysfunction (ED, FSD,PE), cardiovascular & diabetes pharmacology & urology (overactive bladder, bph, detrusor overactivity, interstitial cystitis/Painful bladder syndrome, urinary incontinence).
Receive our news

 

Founded in 1999, PELVIPHARM is a spin-off from the University of Versailles-Saint-Quentin-en-Yvelines (France) relying on multi-disciplinary talents (medical doctor, pharmaco-economist, veterinarian, pharmacists and PhDs) who deliver both high quality academic standards and reliable contract research services :

  • Preclinical studies based on validated efficacy models including delivery of protocol development, study conduct, report, communication and peer-reviewed publication
  • Guidance for selection of new chemical entities including testing with targeted assays according to potential mechanisms of action
  • Identification of new properties or attributes supporting differentiation of medications within the class or between classes
  • Advice in clinical development for new therapeutic indications or enhancements to address unmet medical need or significant commercial opportunities

PELVIPHARM has leading scientific and medical capabilities from unique expertise and experience in pathophysiology, pharmacology, clinical research and medical practice across a range of therapeutic areas including urology (BPH, OAB, NDO, SCI, SUI, IC …), sexual medicine (ED, PE, FSD …) and cardiovascular (Hypertension, Atherosclerosis, Myocardial Infarction …), metabolism and eating disorders (Metabolic Syndrome, Obesity, Diabetes ...)


Cardiovascular fucntion Lower urinary tract Male and female sexual function

PELVIPHARM provides customized services to clients according to their outsourcing needs, using experimental models based on the most recent exploration methods.

PELVIPHARM can give you the unique expertise and the experience of a team gathered over the years.

News and next meetings

Presentations at the SEUD 2022
Pelvipharm at the 8th SEUD Congress 2022 (Society of Endometriosis and Uterine Disorders), May 18–21......

Recently accepted paper in Toxins
BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Function......

Presentations at the Virtual ESSM 2022
Pelvipharm at the 23rd Virtual ESSM Congress 2022 (European Society for Sexual Medicine), February 1......

Latest website updates

New abstract/poster available for download

Ex vivo comparison of three BoNT serotypes in the autonomic nervous system and the neuromuscular junction presented at British Pharmacological Society Meeting, Edinburgh, U.K., Dec 17-19 2019, Maignel et al.

New experimental skills developed

Vaginal blood flow engorgement measurement by Laser Doppler Flowmetry (rat/guinea pig/rabbit)

New model developped

Testosterone-supplemented SHR as a model of BPH / male LUTS

SITEMAP
TEL +331 704 293 39
FAX + 331 704 295 10
LEGAL